Search Result

Results for "

GSK3-IN-3

" in MedChemExpress (MCE) Product Catalog:

標的別:	5-HT Receptor (2) AAK1 (1) Adrenergic Receptor (1) Akt (8) Aminopeptidase (1) AMPK (1) Amyloid-β (14) Androgen Receptor (1) Angiotensin Receptor (1) AP-1 (1) Apoptosis (32) Aurora Kinase (1) Autophagy (17) Bcl-2 Family (3) Beclin1 (1) Beta-secretase (1) Biochemical Assay Reagents (1) c-Myc (2) Cadherin (1) Casein Kinase (1) Caspase (6) CDK (27) CFTR (1) Cholinesterase (ChE) (8) COX (2) Cytochrome P450 (1) Dopamine Receptor (1) DYRK (3) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Epigenetic Reader Domain (2) ERK (6) Ferroptosis (1) FGFR (1) Glucocorticoid Receptor (5) GSK-3 (154) HDAC (2) Histone Methyltransferase (1) HIV (1) HSP (2) HSV (3) IFNAR (1) IKK (1) Integrin (1) Interleukin Related (4) Isotope-Labeled Compounds (3) JAK (7) JNK (5) Keap1-Nrf2 (3) KMO (1) LIM Kinase (LIMK) (1) Lipoxygenase (1) LPL Receptor (2) MAP3K (2) MEK (2) Microtubule/Tubulin (1) Mineralocorticoid Receptor (4) Mitochondrial Metabolism (1) Mitophagy (1) mTOR (1) nAChR (2) NF-κB (9) NO Synthase (1) NOD-like Receptor (NLR) (1) Organoid (7) P-glycoprotein (1) p38 MAPK (4) Parasite (3) PD-1/PD-L1 (1) PDK-1 (1) PI3K (5) Pim (1) PKA (2) PKC (2) PPAR (1) PROTAC Linkers (1) PROTACs (1) Proton Pump (2) RANKL/RANK (1) Ras (1) Reactive Oxygen Species (ROS) (11) Reference Standards (14) Ribosomal S6 Kinase (RSK) (1) Ser/Thr Kinase (1) Sirtuin (1) SOD (1) Src (3) STAT (3) Tau Protein (12) TGF-β Receptor (2) TNF Receptor (5) Wnt (18) β-catenin (20)
研究分野別:	Cancer (89) Cardiovascular Disease (4) Infection (12) Inflammation/Immunology (35) Metabolic Disease (41) Neurological Disease (97)
クリックケミストリー:	PROTAC Synthesis (1)

177

阻害剤およびアゴニスト

蛍光色素

生化学アッセイ試薬

ペプチド

天然物

同位体標識化合物

クリックケミストリー

製品番号	製品名	Target	研究分野	構造式

HY-16294

LY2090314 15+ Cited Publications	GSK-3	Cancer
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

HY-14872

Tideglusib 5+ Cited Publications NP031112	GSK-3	Neurological Disease
Tideglusib (NP031112) is an irreversible *GSK-3* inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β ^WT (1 h preincubation) and GSK-3β ^C199A (1 h preincubation), respectively.

HY-12012

SB 216763 40+ Cited Publications	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 is potent, selective and ATP-competitive *GSK-3* inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

HY-10590

TWS119 30+ Cited Publications	Wnt GSK-3 Autophagy	Neurological Disease Cancer
TWS119 is an inhibitor of *GSK-3β, with an IC₅₀* of 30 nM, and activates the wnt/β-catenin pathway.

HY-12292

IM-12 5+ Cited Publications	Wnt GSK-3	Cancer
IM-12 is an inhibitor of *GSK-3β, with an IC₅₀* of 53 nM, and also enhances Wnt signalling.

HY-59090

1-Azakenpaullone 3 Publications Verification 1-Akp	GSK-3	Neurological Disease Metabolic Disease
1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of glycogen synthase kinase-3 β (GSK-3β), with an IC₅₀ value of 18 nM .

HY-10182G

Laduviglusib 2 Publications Verification CHIR-99021; CT99021	GSK-3 Wnt β-catenin Autophagy	Metabolic Disease Cancer
Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.

HY-15761

AZD2858 5+ Cited Publications	GSK-3	Neurological Disease
AZD2858 is a potent, orally active *GSK-3* inhibitor, with IC₅₀s of 0.9 and 5 nM for *GSK-3α* and *GSK-3β*, respectively, used in the research of fracture healing.

HY-130795

GSK-3β inhibitor 2 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active *GSK-3β* inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-12524

Bikinin 2 Publications Verification AbrasIN	GSK-3	Others
Bikinin is a non-steroidal, ATP-competitive inhibitor of plant GSK-3/Shaggy-like kinases and activates BR (brassinosteroids) signaling.

HY-11012

TDZD-8 10+ Cited Publications GSK-3β INhibitor I; NP 01139	GSK-3	Cancer
TDZD-8 is an inhibitor of *GSK-3β, with an IC₅₀* of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC₅₀s of >100 μM.

HY-153089

*GSK3-IN-3* 4 Publications Verification	GSK-3 Mitophagy	Neurological Disease
GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a *GSK-3* inhibitor with an IC₅₀ value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA .

HY-13076

CHIR-98014 5+ Cited Publications	GSK-3	Metabolic Disease
CHIR-98014 is a potent, cell-permeable *GSK-3* inhibitor with IC₅₀s of 0.65 and 0.58 nM for *GSK-3α* and *GSK-3β*, respectively; it shows less potent activities against cdc2 and erk2.

HY-100207

CP21R7 5+ Cited Publications CP21	GSK-3	Cancer
CP21R7 is potent *GSK-3β* inhibitor, with an IC₅₀ of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC₅₀ of 1900 nM.

HY-107531

A 1070722	GSK-3	Neurological Disease Cancer
A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .

HY-15438

SB 415286 5+ Cited Publications	GSK-3 Apoptosis	Metabolic Disease
SB 415286 is a potent and selective cell permeable inhibitor of *GSK-3α, with an IC₅₀* of 77.5 nM, and a K_i of 30.75 nM; SB 415286 is equally effective at inhibiting human *GSK-3α* and *GSK-3β*.

HY-126144

GSK-3β inhibitor 1 4 Publications Verification	GSK-3	Metabolic Disease Cancer
GSK-3β inhibitor 1 (compound 3a) inhibits *GSK-3β* with an IC₅₀ of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats .

HY-119940

MC180295 1 Publications Verification (rel)-MC180295	CDK	Cancer
MC180295 ((rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC₅₀ of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect .

HY-15356

BIO-acetoxime 2 Publications Verification BIA	GSK-3 Apoptosis HSV	Infection Neurological Disease Inflammation/Immunology
BIO-acetoxime (BIA) is a potent and selective *GSK-3* inhibitor, with IC₅₀s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.

HY-154851

*GSK-3 inhibitor 3*	GSK-3 CDK Tau Protein	Neurological Disease
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of *GSK-3, with IC₅₀s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3* lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC₅₀ of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research .

HY-P10605

GSK3β-peptide	Akt GSK-3	Cancer
GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3-β (GSK3-β) that can bind to the active site of *GSK3-β* and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs .

HY-149845

PROTAC GSK-3β Degrader-1	PROTACs GSK-3	Neurological Disease
PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets *GSK-3β* degradation with an IC₅₀ value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand). PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ_25-35 peptide and CuSO₄. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease .

HY-122026

PF-04802367 PF-367	GSK-3	Neurological Disease
PF-04802367 (PF-367) is a highly selective *GSK-3* inhibitor with an IC₅₀ of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and *GSK-3β) with IC₅₀* values of 10.0 and 9.0 nM in mobility shift assays, respectively .

HY-148561

CDK8-IN-12	CDK GSK-3 PKC	Cancer
CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a K_i of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with K_is of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent .

HY-111930

5-Iodo-indirubin-3'-monoxime	GSK-3 CDK	Cancer
5-Iodo-indirubin-3'-monoxime is a potent *GSK-3β, CDK5/P25* and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC₅₀s of 9, 20 and 25 nM, respectively .

HY-149054

GSK-3β inhibitor 13	GSK-3 Tau Protein AAK1 Pim PKC	Neurological Disease
GSK-3β inhibitor 13 (compound 47) is an orally active and potent *GSK-3β* inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits *GSK-3β* and *GSK-3α* with IC₅₀s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC₅₀=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .

HY-141480

GSK-3β inhibitor 3 1 Publications Verification	GSK-3 Apoptosis	Cancer
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC₅₀ of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .

HY-112388

GSK-3b Inhibitor XI 1 Publications Verification	GSK-3	Neurological Disease Metabolic Disease
GSK-3b Inhibitor XI (Compound 33) is a potent and selective GSK3β inhibitor, with a K_i value of 25 nM. GSK-3b Inhibitor XI increases glycogen synthase (GS) activity. GSK-3b Inhibitor XI can be used for research on type 2 diabetes and Alzheimer’s disease .

HY-144290

ARN25068	GSK-3 DYRK	Neurological Disease
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of *GSK-3, CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-137472

SAR502250	GSK-3	Neurological Disease
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of *GSK3, with an IC₅₀* of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .

HY-155805

SGC-CAF382-1	CDK	Cancer
CAF-382 (compound B1) is an analog of SNS-032 and a CDKL5 and pan-CDK inhibitor with a weak GSK3α/β affinity (>1.8 μM) and inhibitory activity. CAF-382 inhibits CDKL5 and blocks the phosphorylation of the CDKL5 E2 domain .

HY-164907

GSK-3β inhibitor 22	GSK-3	Neurological Disease
GSK-3β inhibitor 22 (compound 20o) is a *GSK-3β* inhibitor with an IC₅₀ of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease .

HY-120902

GSK-3β inhibitor 8	Wnt GSK-3	Inflammation/Immunology
GSK-3β inhibitor 8, a thiophenacil derivative, is an effective and selective inhibitor of *GSK-3β* (IC₅₀=64 nM). GSK-3β inhibitor 8 negatively regulated Wnt signaling pathway and stimulated β cell proliferation .

HY-111055

BIP-135	GSK-3	Neurological Disease
BIP-135 is a potent and selective ATP-competitive *GSK-3* inhibitor, with IC₅₀s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .

HY-W969907

GSK3-IN-7	GSK-3	Others
GSK3a-IN-38 is a groundbreaking small molecule that effectively inhibits GSK-3a activity.

HY-10096

TCS2002	GSK-3	Neurological Disease
TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent *GSK-3β* inhibitor with the IC₅₀ of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .

HY-134393B

6-Me-ATP trisodium solution (100 mM) N6-Methyl-ATP trisodium solution (100 mM)	GSK-3	Others
6-Me-ATP (N6-Methyl-ATP) trisodium solution (100 mM) is a N ⁶-modified ATP derivative. 6-Me-ATP trisodium shows excellent binding affinity to *GSK3, serving as the phosphate group donor for GSK3*β-catalyzed phosphorylation of its substrate peptide .

HY-147134

GSK-3β inhibitor 10	GSK-3	Neurological Disease
GSK-3β inhibitor 10 (compound 14a) is a highly potent *GSK-3β* inhibitor with an IC₅₀ value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .

HY-144826

ZDWX-25	GSK-3	Neurological Disease
ZDWX-25 is a highly potent *GSK-3β* and DYRK1A dual inhibitor with an IC₅₀ value of 71 nM for GSK-3β. ZDWX-25 possesses significant cytotoxic activities against SH-SY5Y and HL-7702 cells. ZDWX-25 can be used for researching alzheimer's disease .

HY-126144A

(E/Z)-GSK-3β inhibitor 1	GSK-3	Metabolic Disease
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM .

HY-176287

ARN25657	Dopamine Receptor GSK-3 PKA P-glycoprotein	Neurological Disease
ARN25657 is a dual-acting D3R/GSK-3β modulator. ARN25657 has both partial D3R agonist activity (EC₅₀ = 15.2 nM, K_i=1.5 nM) and potent *GSK-3β* inhibitor activity (IC₅₀ = 19.3 nM). ARN25657 exhibits excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. ARN25657 inhibits P-glycoprotein (P-gP)-mediated acetoxymethyl calcein efflux and improves in vitro ADME properties while maintaining a balanced dual-target profile. ARN25657 is useful for studying bipolar disorder and related neuropsychiatric disorders .

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

HY-149542

GSK-3β inhibitor 15	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a *GSK-3β* inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-168857

GSK-3β inhibitor 24	GSK-3 Tau Protein β-catenin	Neurological Disease
GSK-3β inhibitor 24 (Compound 41) is a potent *GSK-3β* inhibitor with an IC₅₀ of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects .

HY-175850

GSK-3β-IN-28	GSK-3 Apoptosis NF-κB c-Myc	Cancer
GSK-3β inhibitor 28 is selective and non-competitivea glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC₅₀ of 14.82 nM. GSK-3β inhibitor 28 can upregulate the expression level of phosphorylated GSK-3β and downregulate the expression of p-NF-κB, P65, C-myc and Cyclin D1. GSK-3β inhibitor 28 can induce cells apoptosis, G1 phase arrest and inhibit migration. GSK-3β inhibitor 28 can be used for the research of cancer, such as colorectal cancer .

HY-170491

GSK-3β inhibitor 23	GSK-3	Infection Neurological Disease
GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits *GSK-3β* and *GSK-3α* with IC₅₀ of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability) .

HY-148132

GSK-3β inhibitor 11	GSK-3	Neurological Disease
GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .

HY-W098905

GSK3β-IN-3	GSK-3 Cytochrome P450 Amyloid-β Tau Protein	Neurological Disease
GSK3β-IN-3 is an ATP-competitive *GSK-3β* inhibitor (IC₅₀ = 0.90 μM). GSK3β-IN-3 can reduce the phosphorylation level of tau protein in the BR5706 strain and reduce the deposition of Aβ aggregates in the CL2006 strain, and can be used to research Alzheimer's disease (AD) .

製品番号	製品名	Type

HY-10182G

Laduviglusib 2 Publications Verification CHIR-99021; CT99021	蛍光色素
Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.

HY-16294G

LY2090314	蛍光色素
LY2090314 (GMP) is LY2090314 (HY-16294) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

HY-15244G

Alpelisib

蛍光色素

Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .

製品番号	製品名	Type

HY-10182G

Laduviglusib 2 Publications Verification CHIR-99021; CT99021	生化学アッセイ試薬
Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.

HY-134393B

6-Me-ATP trisodium solution (100 mM) N6-Methyl-ATP trisodium solution (100 mM)	生化学アッセイ試薬
6-Me-ATP (N6-Methyl-ATP) trisodium solution (100 mM) is a N ⁶-modified ATP derivative. 6-Me-ATP trisodium shows excellent binding affinity to *GSK3, serving as the phosphate group donor for GSK3*β-catalyzed phosphorylation of its substrate peptide .

HY-16294G

LY2090314	生化学アッセイ試薬
LY2090314 (GMP) is LY2090314 (HY-16294) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

HY-15244G

Alpelisib

生化学アッセイ試薬

製品番号	製品名	Target	研究分野

HY-P10605

GSK3β-peptide	Akt GSK-3	Cancer
GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3-β (GSK3-β) that can bind to the active site of *GSK3-β* and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs .

HY-P4685

(Sar1,Ile4,8)-Angiotensin II	Angiotensin Receptor	Metabolic Disease
(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .

HY-P1385

TCS 183	GSK-3 p38 MAPK	Neurological Disease
TCS 183, a peptide, is a *GSK-3β* inhibitor. TCS 183 blocks GSK-3β autoinhibition and decreases the level of AMPK phosphorylation. TCS 183 can be used for neuropathological diseases, particularly Alzheimer’s disease, research .

製品番号	製品名	Category	Target	構造式

HY-N0527

Pentagalloylglucose Maximum Cited Publications 15 Publications Verification Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucose	Infection other families Classification of Application Fields Anti-aging Phenols Polyphenols Plants Disease Research Fields Source Classification	JAK Keap1-Nrf2 Apoptosis β-catenin Reactive Oxygen Species (ROS) E1/E2/E3 Enzyme
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the *GSK3β/β-catenin* pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .

HY-N8423

α-Amyrin 1 Publications Verification	Triterpenes other families Terpenoids Plants	ERK GSK-3 Apoptosis Caspase COX
α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and *GSK-3β* signaling pathways. α-Amyrin can inhibit cancer cells proliferation and induce apoptosis. α-Amyrin shows anti-bacterial and anti-inflammation activity. α-Amyrin can reduce blood glucose level. α-Amyrin can be used for the researches of cancer, infection, inflammation, metabolic disease and neurological disease, such as breast cancer, Streptococcus oralis infection, skin inflammation and diabetes .

HY-N6973

Boldine 1 Publications Verification	Alkaloids Classification of Application Fields Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Litsea cubeba (Lour.) Pers. Source Classification	RANKL/RANK Apoptosis
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and *GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK* signaling pathway. It can be used in rheumatoid arthritis research .

HY-N0753

Eupalinolide B	Classification of Application Fields Melilotus albus Desr. Terpenoids Sesquiterpenes Plants Compositae Disease Research Fields Source Classification Cancer	Apoptosis Autophagy Reactive Oxygen Species (ROS) GSK-3 β-catenin MAP3K JNK NF-κB p38 MAPK
Eupalinolide B is a germ sesquiterpene. Eupalinolide B can be isolated from Eupatorium lindleyanum. Eupalinolide B induces Apoptosis, elevates ROS, promotes Autophagy. regulates *GSK-3β/β-catenin, targets UBE2D3* and TAK1, activates ROS-ER-JNK, inhibits NF-κB and MAPKs. Eupalinolide B has anticancer activity against pancreatic cancer and liver cancer. Eupalinolide B relieves rheumatoid arthritis, acute lung injury, periodontitis, depression .

HY-N0815

Resibufogenin 5+ Cited Publications BufogenIN; RecibufogenIN	Animals Classification of Application Fields Disease Research Fields Steroids Source Classification Cancer	PI3K Akt NF-κB AP-1 GSK-3 CDK
Resibufogenin is an orally active anticancer agent. Resibufogenin can be extracted from toad venom. Resibufogenin blocks signaling pathways such as PI3K/Akt, NF-κB, AP-1, activates *GSK-3β, and regulates cyclin D1*. Resibufogenin can activate central neurons. Resibufogenin has anti-inflammatory activity. Resibufogenin has anti-tumor effects on a variety of tumors such as multiple myeloma, renal cancer, colorectal cancer, pancreatic cancer, and glioma .

HY-N1472

Levistolide A 5 Publications Verification	天然物 Classification of Application Fields Dicerothamnus rhinocerotis Umbelliferae Plants Disease Research Fields Source Classification Cancer	Apoptosis Reactive Oxygen Species (ROS) PPAR GSK-3 Tau Protein Ras TGF-β Receptor
Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the *GSK3α/β* pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways .

HY-N11576

Secalonic acid D	天然物 Microorganisms Classification of Application Fields Sunscreen Cosmetic Research Disease Research Fields Cancer Source Classification	Apoptosis GSK-3 c-Myc β-catenin
Secalonic acid D is a toxic compound against tumor cells. Secalonic acid D can be isolated from the metabolites of Aspergillus aculeatus. Secalonic acid D activates *GSK3-β, and degrades β-catenin. Thus, Secalonic acid D down-regulates c-Myc* expression, arrests cell cycle at G1 phase, induces cell apoptosis .

HY-N6580

Ginsenoside Rg4	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Metabolic Disease Plants Inflammation/Immunology Disease Research Fields Araliaceae Source Classification	PI3K Akt GSK-3 Reactive Oxygen Species (ROS) TNF Receptor Interleukin Related
Ginsenoside Rg4 is an orally active protopanaxatriol type ginsenoside. Ginsenoside Rg4 can activate PI3K, AKT and *GSK-3β* signaling. Ginsenoside Rg4 can inhibit ROS and inflammatory cytokine levels. Ginsenoside Rg4 can be used for the researches of inflammation, infection and metabolic disease, such as sepsis and lung inflammation .

HY-117025A

Manzamine A hydrochloride 2 Publications Verification KeramamINe A hydrochloride	Infection Alkaloids Piperidine Alkaloids Neurological Disease Classification of Application Fields Animals Marine natural products Pyridine Alkaloids Sponge Disease Research Fields Indole Alkaloids Source Classification	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically *GSK-3β* and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 .

HY-117025

Manzamine A KeramamINe A	Infection Alkaloids Neurological Disease Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Cancer	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically *GSK-3β* and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1 .

HY-N10359

Isoandrographolide	Acanthaceae Classification of Application Fields Simsia foetida (Cav.) S.F.Blake Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	NOD-like Receptor (NLR) Caspase Akt GSK-3 β-catenin
Isoandrographolide is an orally active NLRP3 inflammasome inhibitor and AKT/GSK-3β/β-catenin pathway inhibitor. Isoandrographolide inhibits the expression of NLRP3, ASC, and caspase-1, and reduces the levels of phosphorylated AKT, phosphorylated GSK-3β, and β-catenin. Isoandrographolide alleviates inflammatory responses, reduces collagen deposition, suppresses epithelial-mesenchymal transition (EMT), induces differentiation of leukemia cells, inhibits the growth of leukemia cells, protects lung and kidney tissues, regulates cytokine levels, and also exhibits hepatoprotective effects. Isoandrographolide can be used in studies related to silicosis, murine myeloid leukemia, renal tubulointerstitial fibrosis, and non-alcoholic fatty liver disease .

HY-N8423R

α-Amyrin (Standard)	Triterpenes Structural Classification other families Terpenoids Plants	Reference Standards ERK GSK-3 Apoptosis Caspase COX
α-Amyrin (Standard) is a pentacyclic triterpenoid compound with oral activity. α-Amyrin (Standard) activates the ERK and *GSK-3β* signaling pathways. α-Amyrin (Standard) can inhibit cancer cells proliferation and induce apoptosis. α-Amyrin (Standard) shows anti-bacterial and anti-inflammation activity. α-Amyrin (Standard) can reduce blood glucose level. α-Amyrin (Standard) can be used for the researches of cancer, infection, inflammation, metabolic disease and neurological disease, such as breast cancer, Streptococcus oralis infection, skin inflammation and diabetes .

HY-N0527R

Pentagalloylglucose (Standard) Penta-O-galloyl-β-D-glucose (Standard); 1,2,3,4,6-Pentagalloyl glucose (Standard)	Structural Classification other families Phenols Polyphenols Plants Source Classification	Reference Standards JAK Keap1-Nrf2 Apoptosis β-catenin Reactive Oxygen Species (ROS)
Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the *GSK3β/β-catenin* pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .

HY-133102

Dihydronarwedine LycoramINone	Alkaloids Other Alkaloids Narcissus pseudonarcissus L. Plants Amaryllidaceae Source Classification	GSK-3
Dihydronarwedine (Lycoraminone) is the alkaloid. Dihydronarwedine inhibits 39% activity of glycogen synthase kinase-3β (GSK-3β) at a concentration of 10 μM .

HY-N0815R

Resibufogenin (Standard) BufogenIN (Standard); RecibufogenIN (Standard)	Structural Classification Animals Steroids Source Classification	Reference Standards Others
Resibufogenin (Standard) is the analytical standard of Resibufogenin. This product is intended for research and analytical applications. Resibufogenin is an orally active anticancer agent. Resibufogenin can be extracted from toad venom. Resibufogenin blocks signaling pathways such as PI3K/Akt, NF-κB, AP-1, activates *GSK-3β, and regulates cyclin D1*. Resibufogenin can activate central neurons. Resibufogenin has anti-inflammatory activity. Resibufogenin has anti-tumor effects on a variety of tumors such as multiple myeloma, renal cancer, colorectal cancer, pancreatic cancer, and glioma .

HY-N17990

Sexangularetin 3-sophoroside	Structural Classification Flavonoids Flavones Rosa hugonis Hemsl. Rosaceae Plants Source Classification	PDK-1 Akt GSK-3 Reactive Oxygen Species (ROS)
Sexangularetin 3-sophoroside is a PDK1 and Akt phosphorylation activator with neuroprotective properties. Sexangularetin 3-sophoroside restores phosphorylated *GSK-3β* protein levels. Sexangularetin 3-sophoroside acts as a ROS inhibitor and regulates mRNA expression of superoxide dismutase 1 and catalase. Sexangularetin 3-sophoroside can be used for the research of Parkinson’s disease .

HY-N19615

Isoeucommin A	Structural Classification 天然物 Pandanus tonkinensis Martelli ex B. C. Stone Plants Pandanaceae Source Classification	Keap1-Nrf2 GSK-3 TNF Receptor Interleukin Related SOD
Isoeucommin A is a lignan compound. Isoeucommin A activates the Nrf2/HO-1 pathway and induces phosphorylation of *GSK-3β. Isoeucommin A reduces the levels of pro-inflammatory cytokines TNF-α, IL-1β* and IL-6, decreases the oxidative stress marker MDA, increases the antioxidants SOD and GSH, and alleviates oxidative stress in mesangial cells. Isoeucommin A alleviates renal tissue injury, improves impaired renal function and enhances the viability of renal tubular epithelial cells in diabetic nephropathy models. Isoeucommin A can be used in the research of diabetic nephropathy .

HY-N17821

Butrin	Structural Classification Flavonoids Flavones Leguminosae Plants Butea monosperma Kuntze Source Classification	Sirtuin Aurora Kinase Akt GSK-3 β-catenin TGF-β Receptor Apoptosis Reactive Oxygen Species (ROS) Wnt NF-κB TNF Receptor Interleukin Related IKK
Butrin is a compound found in Butea monosperma flowers. Butrin reduces expression of SIRT1, AURKB, cyclin D1, pAKT, *GSK-3β, β-catenin, and TGF-3β* expression, enhances apoptosis and ROS production in cancer cells. Butrin downregulates Wnt and NF-κB signaling, mitigates oxidative stress, reduces proinflammatory cytokine (TNF-α, IL-6 and IL-8) production and suppresses neuroinflammation. Butrin inhibits IKK enzyme activity. Butrin can be used for the researches of colorectal cancer, Alzheimer’s disease, and rheumatoid arthritis .

製品番号	製品名	構造式

HY-B1619S

Cromolyn-d5

Cromolyn-d₅ (Cromoglycate-d₅) is the deuterium labeled Cromolyn (HY-B1619). Cromolyn (Cromoglycate) is an orally active GSK-3β inhibitor with an IC₅₀ of 2.0 μM. Cromolyn is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn can be used in the research of bronchial asthma. In addition, Cromolyn has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects .

HY-B1203S

Fludrocortisone-d5

Fludrocortisone-d₅ (9α-Fludrocortisone-d₅) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-B1203S1

Fludrocortisone-d2

Fludrocortisone-d₂ (9α-Fludrocortisone-d₂) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

製品番号	製品名		Classification

HY-182978

Pomalidomide-C3-O-C4-O-C3-NH2		PROTAC Synthesis
Pomalidomide-C3-O-C4-O-C3-NH2 is an E3 ligase ligand-linker conjugate that contains Pomalidomide (HY-10984). Pomalidomide-C3-O-C4-O-C3-NH2 can be used for the synthesis of PROTACs targeting glycogen synthase kinase 3β (GSK-3β), such as PROTAC GSK-3β Degrader-1 (HY-149845) .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: